• Christian Moroy

COVID-19 Vaccine: Needles to the rescue?

Uptake, logistics and targeting will determine if the vaccine can allow life to return to normal. We built an interactive tool that can help explore the key factors standing between us and vaccine success for all regions in the UK.


by Kieran Dale, Christian Moroy and George Batchelor



Last week brought the encouraging news of Pfizer's effective vaccine that could prevent more than 95% of people from getting COVID-19. This was accompanied by Oxford/AstraZeneca’s announcement that their vaccine is up to 90% effective, though their trials are still ongoing.


The end of the pandemic seems to be in sight. While this is undoubtedly very positive news, many hurdles remain before ending the pandemic is a reality.


There are still many unsolved problems. The necessary regulatory approval that the vaccines are safe to distribute is ongoing. Logistically, producing and transporting vaccines at scale is also a huge challenge. For example Pfizer’s MRNA vaccine typically needs to be stored at -70C, and two doses are required within a strict timeframe).


Efforts are being made to ensure worldwide equitable access to the vaccine, which range in price from Oxford’s (£2.23) to Pfizer’s (£29.47). There are concerns that mutations of the virus could undermine the vaccine effort. In all cases, vaccinating the vulnerable should be the priority, though decisions are yet to be finalised on who should receive the vaccine first.

Supposing all these problems are overcome, the only question that we need to answer is: would I take the vaccine?


How likely are people to take the vaccine?